Clinical and neuroimaging precursors in cerebral amyloid angiopathy: impact of the Boston criteria version 2.0
European Journal of Neurology · 2024
DOI: 10.1111/ene.16425 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Stefan Weidauer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Neuroimaging, Magnetic Resonance Imaging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose Although the Boston criteria version 2.0 facilitates the sensitivity of cerebral amyloid angiopathy (CAA) diagnosis, there are only limited data about precursor symptoms. This study aimed to determine the impact of neurological and imaging features in relation to the time of CAA diagnosis.
Methods
Patients diagnosed with probable CAA according to the Boston criteria version 1.5, treated between 2010 and 2020 in our neurocentre, were identified through a keyword search in our medical database. Neuroimaging was assessed using Boston criteria versions 1.5 and 2.0. Medical records with primary focus on the clinical course and the occurrence of transient focal neurological episodes were prospectively evaluated.
Results
Thirty‐eight out of 81 patients (46.9%) exhibited transient focal neurological episodes, most often sensory (13.2%) or aphasic disorders (13.2%), or permanent deficits at a mean time interval of 31.1 months (SD ±26.3; range 1–108 months) before diagnosis of probable CAA (Boston criteria version 1.5). If using Boston criteria version 2.0, all patients receiving magnetic resonance imaging (MRI) met the criteria for probable CAA, and diagnosis could have been made on average 44 months earlier. Four patients were younger than 50 years, three of them with supporting pathology. Cognitive deficits were most common (34.6%) at the time of diagnosis.
Conclusions
Non‐haemorrhagic MRI markers enhance the sensitivity of diagnosing probable CAA; however, further prospective studies are proposed to establish a minimum age for inclusion. As the neurological overture of CAA may occur several years before clinical diagnosis, early clarification by MRI including haemosensitive sequences are suggested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
- Department of Neurology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
ORCID-Profile: Stefan Weidauer, Christian Förch, Elke Hattingen, Christophe T Arendt, Lucie Friedauer
Zitieren
APA
Weidauer, S., Tafreshi, M., Förch, C., Hattingen, E., Arendt, C. T., & Friedauer, L. (2024). Clinical and neuroimaging precursors in cerebral amyloid angiopathy: impact of the Boston criteria version 2.0. European Journal of Neurology. https://doi.org/10.1111/ene.16425
Vancouver
Weidauer S, Tafreshi M, Förch C, Hattingen E, Arendt CT, Friedauer L. Clinical and neuroimaging precursors in cerebral amyloid angiopathy: impact of the Boston criteria version 2.0. European Journal of Neurology. 2024. doi:10.1111/ene.16425
BibTeX
@article{Weidauer2024,
author = {Weidauer, Stefan and Tafreshi, Mona and Förch, Christian and Hattingen, Elke and Arendt, Christophe T and Friedauer, Lucie},
title = {Clinical and neuroimaging precursors in cerebral amyloid angiopathy: impact of the Boston criteria version 2.0},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16425}
}
EUVIMED